These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 15452187

  • 1. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy.
    Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, Rowland KM, Alberts SR, Krook JE, Levitt R, Morton RF.
    J Clin Oncol; 2005 Apr 20; 23(12):2606-17. PubMed ID: 15452187
    [Abstract] [Full Text] [Related]

  • 2. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy.
    Chang J, Couture F, Young S, McWatters KL, Lau CY.
    J Clin Oncol; 2005 Apr 20; 23(12):2597-605. PubMed ID: 15452188
    [Abstract] [Full Text] [Related]

  • 3. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
    Voravud N, Sriuranpong V, Suwanrusme H.
    J Med Assoc Thai; 2007 Jun 20; 90(6):1082-8. PubMed ID: 17624200
    [Abstract] [Full Text] [Related]

  • 4. Early Intervention with epoetin alfa during platinum-based chemotherapy: an analysis of quality-of-life results of a multicenter, randomized, controlled trial compared with population normative data.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 20; 11(2):197-205. PubMed ID: 16476840
    [Abstract] [Full Text] [Related]

  • 5. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
    Voravud N, Sriuranpong V.
    J Med Assoc Thai; 2005 May 20; 88(5):607-12. PubMed ID: 16149676
    [Abstract] [Full Text] [Related]

  • 6. Epoetin alfa corrects anemia and improves quality of life in patients with hematologic malignancies receiving non-platinum chemotherapy.
    Littlewood TJ, Nortier J, Rapoport B, Pawlicki M, de Wasch G, Vercammen E, Schuette W, Wils J, Freund M, Epoetin Alfa Study Group.
    Hematol Oncol; 2003 Dec 20; 21(4):169-80. PubMed ID: 14735555
    [Abstract] [Full Text] [Related]

  • 7. A new induction schedule of epoetin alfa 40.000 IU in anemic patients with advanced lung cancer.
    Ariganello O, Mancuso A, Di Molfetta M, Diana F, Beccaglia P, Cortesi E, De Marinis F.
    Lung Cancer; 2004 Oct 20; 46(1):119-24. PubMed ID: 15364140
    [Abstract] [Full Text] [Related]

  • 8. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.
    Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, Szechtman B, Roa W, Mulroy L, Rudinskas L, Gagnon B, Okawara GS, Levine MN.
    J Clin Oncol; 2007 Mar 20; 25(9):1027-32. PubMed ID: 17312332
    [Abstract] [Full Text] [Related]

  • 9. Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.
    Chu E, Einhorn LH, Lefebvre P.
    J Support Oncol; 2006 May 20; 4(5):243-50. PubMed ID: 16724648
    [Abstract] [Full Text] [Related]

  • 10. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy.
    Shasha D, George MJ, Harrison LB.
    Cancer; 2003 Sep 01; 98(5):1072-9. PubMed ID: 12942577
    [Abstract] [Full Text] [Related]

  • 11. Epoetin alfa 60,000 U once weekly followed by 120,000 U every 3 weeks increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy.
    Patton J, Kuzur M, Liggett W, Miranda F, Varsos H, Porter L.
    Oncologist; 2004 Sep 01; 9(1):90-6. PubMed ID: 14755018
    [Abstract] [Full Text] [Related]

  • 12. Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
    Savonije JH, van Groeningen CJ, Wormhoudt LW, Giaccone G.
    Oncologist; 2006 Feb 01; 11(2):206-16. PubMed ID: 16476841
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Grote T, Yeilding AL, Castillo R, Butler D, Fishkin E, Henry DH, DeLeo M, Fink K, Sullivan DJ.
    J Clin Oncol; 2005 Dec 20; 23(36):9377-86. PubMed ID: 16361638
    [Abstract] [Full Text] [Related]

  • 14. Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial.
    Engert A, Josting A, Haverkamp H, Villalobos M, Lohri A, Sökler M, Zijlstra J, Sturm I, Topp MS, Rank A, Zenz T, Vogelhuber M, Nogova L, Borchmann P, Fuchs M, Flechtner HH, Diehl V.
    J Clin Oncol; 2010 May 01; 28(13):2239-45. PubMed ID: 20368566
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
    Vincent JL, Spapen HD, Creteur J, Piagnerelli M, Hubloue I, Diltoer M, Roman A, Stevens E, Vercammen E, Beaver JS.
    Crit Care Med; 2006 Jun 01; 34(6):1661-7. PubMed ID: 16607233
    [Abstract] [Full Text] [Related]

  • 16. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
    Tsuboi M, Ezaki K, Tobinai K, Ohashi Y, Saijo N.
    Jpn J Clin Oncol; 2009 Mar 01; 39(3):163-8. PubMed ID: 19164318
    [Abstract] [Full Text] [Related]

  • 17. Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies.
    Straus DJ, Testa MA, Sarokhan BJ, Czuczman MS, Tulpule A, Turner RR, Riggs SA.
    Cancer; 2006 Oct 15; 107(8):1909-17. PubMed ID: 16977654
    [Abstract] [Full Text] [Related]

  • 18. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
    Razzouk BI, Hord JD, Hockenberry M, Hinds PS, Feusner J, Williams D, Rackoff WR.
    J Clin Oncol; 2006 Aug 01; 24(22):3583-9. PubMed ID: 16877725
    [Abstract] [Full Text] [Related]

  • 19. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study.
    Aapro M, Leonard RC, Barnadas A, Marangolo M, Untch M, Malamos N, Mayordomo J, Reichert D, Pedrini JL, Ukarma L, Scherhag A, Burger HU.
    J Clin Oncol; 2008 Feb 01; 26(4):592-8. PubMed ID: 18235117
    [Abstract] [Full Text] [Related]

  • 20. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study.
    Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, Makhson A, Roth A, Dodwell D, Baselga J, Biakhov M, Valuckas K, Voznyi E, Liu X, Vercammen E.
    J Clin Oncol; 2005 Sep 01; 23(25):5960-72. PubMed ID: 16087945
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.